A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
13 Nov 2023
Historique:
received: 12 06 2023
accepted: 23 10 2023
medline: 14 11 2023
pubmed: 13 11 2023
entrez: 12 11 2023
Statut: epublish

Résumé

Vaccination has played a pivotal role in reducing the burden of COVID-19. Despite numerous studies highlighting its benefits in reducing the risk of severe disease and death, we still lack a quantitative understanding of how varying vaccination roll-out rates influence COVID-19 mortality. We developed a framework for estimating the number of avertable COVID-19 deaths (ACDs) by vaccination in Iran. To achieve this, we compared Iran's vaccination roll-out rates with those of eight model countries that predominantly used inactivated virus vaccines. We calculated net differences in the number of fully vaccinated individuals under counterfactual scenarios where Iran's per-capita roll-out rate was replaced with that of the model countries. This, in turn, enabled us to determine age specific ACDs for the Iranian population under counterfactual scenarios where number of COVID-19 deaths are estimated using all-cause mortality data. These estimates covered the period from the start of 2020 to 20 April 2022. We found that while Iran would have had an approximately similar number of fully vaccinated individuals under counterfactual roll-out rates based on Bangladesh, Nepal, Sri Lanka, and Turkey (~ 65-70%), adopting Turkey's roll-out rates could have averted 50,000 (95% confidence interval: 38,100-53,500) additional deaths, while following Bangladesh's rates may have resulted in 52,800 (17,400-189,500) more fatalities in Iran. Surprisingly, mimicking Argentina's slower roll-out led to only 12,600 (10,400-13,300) fewer deaths, despite a higher counterfactual percentage of fully vaccinated individuals (~ 79%). Emulating Montenegro or Bolivia, with faster per capita roll-out rates and approximately 50% counterfactual full vaccination, could have prevented more deaths in older age groups, especially during the early waves. Finally, replicating Bahrain's model as an upper-bound benchmark, Iran could have averted 75,300 (56,000-83,000) deaths, primarily in the > 50 age groups. Our analysis revealed that faster roll-outs were consistently associated with higher numbers of averted deaths, even in scenarios with lower overall coverage. This study offers valuable insights into future decision-making regarding infectious disease epidemic management through vaccination strategies. It accomplishes this by comparing various countries' relative performance in terms of timing, pace, and vaccination coverage, ultimately contributing to the prevention of COVID-19-related deaths.

Sections du résumé

BACKGROUND BACKGROUND
Vaccination has played a pivotal role in reducing the burden of COVID-19. Despite numerous studies highlighting its benefits in reducing the risk of severe disease and death, we still lack a quantitative understanding of how varying vaccination roll-out rates influence COVID-19 mortality.
METHODS METHODS
We developed a framework for estimating the number of avertable COVID-19 deaths (ACDs) by vaccination in Iran. To achieve this, we compared Iran's vaccination roll-out rates with those of eight model countries that predominantly used inactivated virus vaccines. We calculated net differences in the number of fully vaccinated individuals under counterfactual scenarios where Iran's per-capita roll-out rate was replaced with that of the model countries. This, in turn, enabled us to determine age specific ACDs for the Iranian population under counterfactual scenarios where number of COVID-19 deaths are estimated using all-cause mortality data. These estimates covered the period from the start of 2020 to 20 April 2022.
RESULTS RESULTS
We found that while Iran would have had an approximately similar number of fully vaccinated individuals under counterfactual roll-out rates based on Bangladesh, Nepal, Sri Lanka, and Turkey (~ 65-70%), adopting Turkey's roll-out rates could have averted 50,000 (95% confidence interval: 38,100-53,500) additional deaths, while following Bangladesh's rates may have resulted in 52,800 (17,400-189,500) more fatalities in Iran. Surprisingly, mimicking Argentina's slower roll-out led to only 12,600 (10,400-13,300) fewer deaths, despite a higher counterfactual percentage of fully vaccinated individuals (~ 79%). Emulating Montenegro or Bolivia, with faster per capita roll-out rates and approximately 50% counterfactual full vaccination, could have prevented more deaths in older age groups, especially during the early waves. Finally, replicating Bahrain's model as an upper-bound benchmark, Iran could have averted 75,300 (56,000-83,000) deaths, primarily in the > 50 age groups.
CONCLUSIONS CONCLUSIONS
Our analysis revealed that faster roll-outs were consistently associated with higher numbers of averted deaths, even in scenarios with lower overall coverage. This study offers valuable insights into future decision-making regarding infectious disease epidemic management through vaccination strategies. It accomplishes this by comparing various countries' relative performance in terms of timing, pace, and vaccination coverage, ultimately contributing to the prevention of COVID-19-related deaths.

Identifiants

pubmed: 37953291
doi: 10.1186/s12916-023-03127-8
pii: 10.1186/s12916-023-03127-8
pmc: PMC10642021
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

429

Informations de copyright

© 2023. The Author(s).

Références

Lancet Respir Med. 2021 Jul;9(7):694-695
pubmed: 33932347
Lancet Infect Dis. 2022 Mar;22(3):302-304
pubmed: 34562376
Clin Infect Dis. 2022 Oct 12;75(8):1442-1445
pubmed: 35412612
Nature. 2023 Jan;613(7942):130-137
pubmed: 36517599
BMJ. 2022 May 31;377:e069989
pubmed: 35640925
Lancet Infect Dis. 2022 Sep;22(9):1293-1302
pubmed: 35753318
Lancet Reg Health West Pac. 2022 Dec 02;29:100654
pubmed: 36471699
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-3
pubmed: 33684019
Nature. 2022 Nov;611(7935):332-345
pubmed: 36329272
Nature. 2006 Jul 27;442(7101):448-52
pubmed: 16642006
Nat Commun. 2022 May 31;13(1):3015
pubmed: 35641529
Elife. 2021 Jun 30;10:
pubmed: 34190045
PLoS Comput Biol. 2021 Sep 2;17(9):e1009288
pubmed: 34473693
Eur J Epidemiol. 2023 Apr 24;:
pubmed: 37093505
Gastroenterol Hepatol Bed Bench. 2022 Spring;15(2):103-105
pubmed: 35845303
BMJ. 2022 Apr 27;377:e069317
pubmed: 35477670
BMC Med. 2023 Mar 8;21(1):85
pubmed: 36882868
BMJ. 2021 Jan 29;372:n281
pubmed: 33514535
JAMA. 2020 Jun 23;323(24):2462-2463
pubmed: 32379268
Lancet Infect Dis. 2021 May;21(5):602-603
pubmed: 33600759
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211065628
pubmed: 34911394
Lancet Reg Health Am. 2023 Jan;17:100397
pubmed: 36439909
BMJ Open. 2019 Sep 18;9(9):e028922
pubmed: 31537561
Philos Trans A Math Phys Eng Sci. 2023 Oct 9;381(2257):20230211
pubmed: 37611626
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Respirology. 2022 Apr;27(4):301-310
pubmed: 34820940
Int J Infect Dis. 2021 Jun;107:101-115
pubmed: 33862214
Public Health Rev. 2023 Jun 02;44:1605601
pubmed: 37332396
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S400-3
pubmed: 6740081
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Euro Surveill. 2021 Nov;26(47):
pubmed: 34823641
Health Policy. 2022 Apr;126(4):281-286
pubmed: 35101288
EClinicalMedicine. 2021 May;35:100865
pubmed: 33937735
Nature. 2020 Aug;584(7822):506-507
pubmed: 32839593
EClinicalMedicine. 2022 Aug 27;53:101624
pubmed: 36051247
Nat Commun. 2022 Jun 9;13(1):3215
pubmed: 35680857
JAMA Netw Open. 2022 Jan 4;5(1):e2142725
pubmed: 35015067
Lancet. 2022 Apr 16;399(10334):1469-1488
pubmed: 35219376
JAMA Netw Open. 2023 May 1;6(5):e2310302
pubmed: 37133864
Epidemics. 2021 Sep;36:100472
pubmed: 34153623

Auteurs

Mahan Ghafari (M)

Big Data Institute and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. mahan.ghafari@ndm.ox.ac.uk.
Department of Biology, University of Oxford, Oxford, UK. mahan.ghafari@ndm.ox.ac.uk.

Sepanta Hosseinpour (S)

School of Dentistry, The University of Queensland, Herston, QLD 4006, Australia.

Mohammad Saeid Rezaee-Zavareh (MS)

Middle East Liver Diseases (MELD) Center, Tehran, Iran.

Stefan Dascalu (S)

Department of Biology, University of Oxford, Oxford, UK.

Somayeh Rostamian (S)

Department of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.

Kiarash Aramesh (K)

The James F. Drane Bioethics Institute, PennWest University, Edinboro, PA, USA.

Kaveh Madani (K)

United Nations University Institute for Water, Environment and Health (UNU-INWEH), Hamilton, ON, Canada.

Shahram Kordasti (S)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. shahram.kordasti@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH